RAPT Therapeutics RAPT 深 沪
等待开盘 07-02 09:30:00 美东时间
58.02
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 58.02
- 总市值 168.03万
- 52周最高 58.02
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.6656
- 委 比 0.00%
- 总股本 2.90万
- 历史最高 409.68
- 量 比 0
- 振 幅 0.00%
- 历史最低 5.6656
- 每 手 1
- 风险率 15.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK溢价40%以106亿美元收购Nuvalent，加码肺癌精准治疗
英国制药巨头葛兰素史克宣布与美国生物技术公司Nuvalent达成收购协议，将以每股124美元现金收购后者所有流通股，交易总价值约106亿美元，较Nuval...
06-09 20:54
葛兰素史克百亿收购Nuvalent，肺癌靶向药管线再落重子
英国制药巨头葛兰素史克周二宣布，已达成协议以106亿美元收购美国生物技术公司Nuvalent。受此消息刺激，Nuvalent股价盘前大涨近39%，逼近每股...
06-09 20:00
UPDATE 5-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
UPDATE 5-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover Deal values cancer drug developer Nuvalent at $124 per share That is a 40% premium to the US-listed firm's close on Monday GSK CEO Miels says deals expands lung cancer treatments Deal size a departure from smaller bolt-on deal
06-09 14:06
“疯狂扫货、近乎不计成本”：生物医药并购如火如荼
核心要点 风投研究机构 PitchBook 统计：2026 年迄今，全球生物医药已落地 201 笔并购，交易总规模达 1060 亿美元。 即便受伊朗冲突...
06-04 17:22
GSK的400亿英镑野心：中国药企能助几分力？
（来源：深蓝观） 吴妮 | 撰文 又一 | 编辑 在圣地亚哥AACR大会的聚光灯下，GSK带来了与翰森合作的B7-H3 ADC多项临床前...
04-27 10:04
GSK Buys RAPT Therapeutics to Bolster Long-Acting Food Allergy Pipeline
GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK has completed its $2....
03-03 23:02
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play
GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary hypertension affecting millions worldwide.
02-25 20:22
葛兰素史克(GSK.US)9.5亿美元收购35 Pharma，发力心血管药物赛道
葛兰素史克(GSK.US)已同意收购 35Pharma Inc.，这是一家拥有早期高血压药物资产的生物技术公司。此举标志着这家英国制药巨头正向心血管药物领域扩张...
02-25 16:45
UPDATE 2-GSK to buy 35Pharma for $950 million in CEO Miel's second major deal
UPDATE 2-GSK to buy 35Pharma for $950 million in CEO Miel's second major deal Acquisition boosts drugmaker's pipeline of respiratory medicines 35Pharma's drug has shown promise in mouse studies for obesity-related heart condition GSK shares have risen nearly 21% so far this year Rewrites paragraphs
02-25 15:27
GSK wins approval of Exdensur in Europe for severe asthma
The European Commission has approved GSK's (GSK) Exdensur (depemokimab) for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. Approval was based on the results fro...
02-17 22:07
